Showing posts with label complex decongestive therapy. Show all posts
Showing posts with label complex decongestive therapy. Show all posts

Sunday, December 09, 2012

Quality of life among breast cancer patients with lymphedema: a systematic review of patient-reported outcome instruments and outcomes.


Quality of life among breast cancer patients with lymphedema: a systematic review of patient-reported outcome instruments and outcomes.


Dec 2012

Source

Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA, pusica@mskcc.org.

Abstract


PURPOSE:

Lymphedema following breast cancer surgery remains a common and feared treatment complication. Accurate information on health-related quality of life (HRQOL) outcomes among patients with lymphedema is critically needed to inform shared medical decision making and evidence-based practice in oncologic breast surgery. Our systematic review aimed to (1) identify studies describing HRQOL outcomes in breast cancer-related lymphedema (BCRL) patients, (2) assess the quality of these studies, and (3) assess the quality and appropriateness of the patient-reported outcome (PRO) instruments used.

METHODS:

Using the PRISMA statement, we performed a systematic review including studies describing HRQOL outcomes among BCRL patients. Studies were classified by levels of evidence and fulfillment of the Efficace criteria. PRO instruments were assessed using the COSMIN criteria.

RESULTS:

Thirty-nine studies met inclusion criteria, including 8 level I and 14 level II studies. Sixteen of 39 studies were compliant with the Efficace criteria. Seventeen HRQOL instruments were used, two specific to lymphedema patients. Exercise and complex decongestive therapy treatment interventions were associated with improved HRQOL.

CONCLUSIONS:

High-quality data on HRQOL outcomes is required to inform surgical decisions for breast cancer management and survivors. Of the lymphedema-specific PRO instruments, the Upper Limb Lymphedema 27 (ULL-27) was found to have strong psychometric properties. Future studies should strive to use high-quality condition- specific PRO instruments, follow existing guidelines for HRQOL measurement and to consider economic burdens of BCRL.

IMPLICATIONS FOR CANCER SURVIVORS:

As lymphedema may develop many years after breast cancer surgery, the ULL-27 may offer greater content validity for use in survivorship research.

Tuesday, September 11, 2012

Management of lymphedema.


Management of lymphedema.


Jul 2012

Source

Dermatovenereology Department, Charles University 2nd Medical School and Bulovka Hospital, Prague, Czech Republic.

Abstract


The basic principle of the management of lymphedema is so called complex decongestive physical therapy. This therapy is divided into two phases: (i) edema reduction phase - an initial intensive treatment phase aiming for limb volume reduction; and (ii) maintenance phase - following long-term phase to sustain a manageable limb volume. The first phase consists of a number of physical therapeutic approaches which are: manual lymph drainage, pneumatic pump drainage, low-stretch bandaging, exercises, and skin care. Long-term maintenance phase consists of self-lymph drainage, low-stretch bandaging, or compressive garments, and sometimes when indicated pneumatic pump drainage, exercises, and skin care.

Wednesday, August 29, 2012

IMPORTANT NOTICE WHICH MAY CHANGE YOUR ACCESS TO LYMPHEDEMA SERVICES IN 2014

IMPORTANT NOTICE WHICH MAY CHANGE YOUR ACCESS TO LYMPHEDEMA SERVICES IN 2014

WE HAVE ONLY UNTIL SEPT 4, 2012, TO RESPOND TO THIS!!  It is up to us to have our voices heard VERY loudly on this. 

Medicare Part B

CLAIMS-BASED DATA COLLECTION STRATEGY FOR THERAPY SERVICES PROPOSED

CMS issued proposed rule, CMS1590P, on July 6 that includes a proposal to collect data on patient function related to physical and occupational therapy, and speech language pathology services. Section 3005(g) of the Middle Class Tax Relief and Jobs Creation Act (MCTRJCA) requires CMS to implement, beginning on January 1, 2013, ". . . a claims based data collection strategy that is designed
to assist in reforming the Medicare payment system for outpatient therapy services subject to the limitations of section 1833(g) of the Act.

Such strategy shall be designed to provide for the collection of data on patient function during the course of therapy services in order to better understand patient condition and outcomes."

The proposed appeared in the July 30, 2012 Federal Register. CMS will accept comments on the proposed rule until September 04, 2012, and will respond to them in a final rule with comment period to be issued by November 1, 2012.

The Problem:
1. New non-payable data collection codes for reporting functional limitations for each claim;
2. Goal is new therapist reimbursement based on improvement of function and complexity of services;
3. Proposed criteria for evaluating improvement of functional limitations are all physical measures There are no measures proposed that would measure
lymphedema severity or improvement of lymphatic function;

Action:

Write a letter to CMS pointing out the impact the new rule will have to you, as a lymphedema patient, if there are no quality measures appropriate to describe the severity/complexity of the “functional limitation” of lymphedema, and
therefore neither the severity/complexity of the functional limitation, nor the progress attained by the therapist. This lack of means of describing and
evaluating the improvement achieved by lymphedema therapy could result in the
incorrect conclusion that the therapy is of no medical value and disapproved.

To be assured consideration, comments must be received at one of the addresses provided below, no later than 5 p.m. on September 4, 2012.

ADDRESSES: In commenting, please refer to file code CMS–1590–P. Because of staff and resource limitations, we cannot accept comments by facsimile (FAX) transmission. You may submit comments in one of four ways (please choose only
one of the ways listed):

1. Electronically. You may submit electronic comments on this regulation to regulations
http://www.regulations.gov. Follow the instructions for ``submitting a comment.''

2. By regular mail. You may mail written comments to the following address ONLY:
Centers for Medicare & Medicaid Services, Department of Health and Human
Services, Attention: CMS–1590–P, P.O. Box 8013, Baltimore, MD 21244–8013.

Please allow sufficient time for mailed comments to be received before the close
of the comment period.

3. By express or overnight mail. You may send written comments to the following address ONLY: Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS–1590–P, Mail Stop C4–26–05, 7500 Security Boulevard, Baltimore, MD 21244–1850.

4. By hand or courier. If you prefer, you may deliver (by hand or courier) your written comments before the close of the comment period to either of the
following addresses:

a. For delivery in Washington, DC— Centers for Medicare & Medicaid Services,
Department of Health and Human Services, Room 445–G, Hubert H. Humphrey
Building, 200 Independence Avenue SW., Washington, DC 20201. (Because access to
the interior of the Hubert H. Humphrey Building is not readily available to persons without Federal government identification, commenters are encouraged to leave their comments in the CMS drop slots located in the main lobby of the building. A stamp-in clock is available for persons wishing to retain a proof of filing by stamping in and retaining an extra copy of the comments being filed.)

b. For delivery in Baltimore, MD— Centers for Medicare & Medicaid Services,
Department of Health and Human Services, 7500 Security Boulevard, Baltimore, MD
21244–1850. If you intend to deliver your comments to the Baltimore address, please call telephone number (410) 786– 7195 in advance to schedule your arrival with one of our staff members. Comments mailed to the addresses indicated as appropriate for hand or courier delivery may be delayed and received after the comment period.

Robert Weiss, M.S.
Lymphedema Patient Advocate
National Lymphedema Network

Tuesday, November 04, 2008

Supplemental surgical treatment to end stage (stage IV-V) of chronic lymphedema.

Normally, I don't post articles suggesting surgeries on lymphedema. Due to the complications that have been experienced by lymphedema patients, I am strongly opposed to what we call a debulking surgery.

However, this study is interesting for a couple reason. The surgery appears to be one I have never heard of - Auchincloss-Homan's procedure and references to stages IV-V which they call "end-Stage" lymphedema.

I research those items to see what I can find and of course will post the info.

In the meantime, here is the abstract.

Supplemental surgical treatment to end stage (stage IV-V) of chronic lymphedema.

Int Angiol. 2008 Oct

Lee BB, Kim YW, Kim DI, Hwang JH, Laredo J, Neville R.
Department of Surgery, Georgetown University, Washington DC, USA.

AIM: When the lymphedema reaches to its end stages, the complex decongestive therapy (CDT) and/or compression therapy become less effective and increased risk of systemic/general sepsis to become potentially life threatening condition.

METHODS: To improve its clinical management, excisional surgery was performed on 22 patients for their 33 limbs in the end stage of lymphedema as a supplemental therapy, and its efficacy was retrospectively analyzed. Diagnosis was made by radionuclide lymphoscintigraphy and basic laboratory studies (e.g. ultrasonography, magnetic resonance imaging). Twenty-two patients (mean age: 46 years; 3 male and 19 female; 5 primary and 17 secondary) submitted to the excisional surgery on 33 limbs (unilateral: 11; bilateral: 22). Surgery was indicated by further progression of the disease with recurrent sepsis despite adequate antibiotics therapy. A modified Auchincloss-Homan's operation was used to excise grotesquely disfigured soft tissue with advanced dermato-lipo-fibrosclerotic change. The normal limb contour was re-established to allow proper postoperative therapy. Postoperative CDT and compression therapy were mandatorily implemented in all cases.

RESULTS: A postoperative assessment of the treatment results, at 12 months showed an overall improvement in 28 of the 33 limbs: substantial improvement on the condition of limb function and quality of life (QOL), and local and/or systemic sepsis. Eighteen patients with good compliance to maintain the postoperative CDT showed much improved clinical results and QOL through the first interim assessment (24 months).

CONCLUSION: Excisional surgery at the end stage of lymphedema seems to provide substantial improvement of clinical condition and QOL only when mandated postoperative CDT/compression therapy is well kept.


PMID: 18974701 [PubMed - in process]

Sunday, February 11, 2007

Lymphedema - Just Live With It


Lymphedema - "Just Live with It"
.
Barbara Pilvin
.
February 2007
.
For four decades that was all I was offered. Did the increasingly severe swelling, first in my right foot, ankle and lower leg, then in the left as well, bother me? How about the blisters that accompanied it? They would start small, then grow and sprout new ones, oozing on my skin, my socks, my sheets. What about the fiery streaks, spots and blotches on my lower extremities, the bruises that never went away? And the aches, the sense of pressure in my feet that made me wonder if they would keep puffing up like balloons...and then pop?
.
“What are you COMPLAINING about?” people would ask when I told them any of that. Their eyes would travel as they spoke, from my feet, ankles and legs to my face, and they would add, “No one notices your legs, Barbara!”
.
None of them had any such complaints, of course, and since neither they nor any doctor I saw knew what was wrong, everyone assumed I was just “whining” about a problem that only existed in my mind. They ignored the fact that lower-extremity swelling plagued both my father’s mother and older brother, and that mine had never completely disappeared since the afternoon it had begun, in December 1961, when I was 10, with an inexplicably painful (but not swollen) right ankle, followed the next morning by blotches and streaks with terrible (but painless) ankle swelling. After five or six years with that swelling, I decided everyone must be right, and vowed to be stoical about it.
.
But that didn’t make it go away. In fact, it got worse. So did my fear of it, for if it kept getting worse, what could it do to me? Could it kill me? It could certainly cripple me. By 1969, my first year in college, it affected both legs, and the blisters were unsightly, itchy, painful and chronic. Sometimes my feet were so swollen I couldn’t wear shoes. I remember the evening a friend came to my dorm room, tried to get me to join her and others at a party, and gasped when I tearfully showed her my feet.
.
In graduate school in the mid-‘70's, I was told by my doctor that the problem was called lymphedema, and that there was no treatment for it. Again, it was “just live with it.”
.
In mid-August 2002 I skinned a toe in a hotel swimming pool. Basic first-aid measures notwithstanding, within four days I had cellulitis, a bacterial infection that can be life- and limb-threatening. While recuperating, I read enough to know that, if I did indeed have lymphedema, I was in a high-risk group for more such infections...and that there actually was a means of treating it. I demanded a diagnosis, and knew within three weeks that I had primary lymphedema.
.
Today, thanks to diligent treatment, my lower extremities look very attractive. With my open-toe prescription compression stockings, custom-made toecaps (they look like gloves with open fingertips), special foam under the toecaps with divets cut to follow the line of the metatarsals, and non-prescription compression stockings (my idea), no one can tell there’s anything seriously wrong with my legs. The left looks a bit larger than the right, but not enough to draw attention. I can wear normal shoes, and only occasionally have skin infections. This is because the lymphatic fluid, which contains bacteria and other toxins, is moving better through my genetically-inadequate lymphatic system, thanks to those compression garments and the other medical devices that are an essential component of the only standard treatment for lymphedema. It’s called CDT, for complex (or complete or comprehensive) decongestive therapy, and the garments are the daytime key, while compression sleeves or short-stretch bandages and accessories are the nighttime key, as well as the 24/7 key for initial treatment.
.
Sounds good, right? Well, it’s better than nothing, and I’m a lot better off than many others with lymphedema. Any cancer survivor whose treatment includes lymph-node removal or irradiation is at risk for it, and about 30% of this country’s three million breast cancer survivors have it, according to the Lymphatic Research Foundation. So do survivors of other cancers, injury, and surgery, while only about one in 6,000-10,000 people, like me, inherit it, developing it either in childhood or adolescence (some are born with it), or as adults. Worldwide, millions of people develop it as a result of a mosquito-born parasite. This form is called filariasis, and in the photos I’ve seen, it causes elephantiasis: stage 3 lymphedema.
.
Mine had hit late stage 2 by the time it was diagnosed. Why not stage 3? I was smart and lucky: I had taken good care of my skin and kept my weight down by walking, swimming, skating, biking, watching what I ate and being blessed with some slimness genes.
.
I was lucky in another sense, too: I had access to expert professional care and insurance that covered my prescription stockings and toecaps.
I’m no longer so lucky. My insurance plan, like so many others, has followed the lead of Medicare, which now terms “secondary surgical dressings” the expensive compression garments that people with lymphedema need to remain healthy. In other words, the garments aren’t covered. Without them, the effects of the disease on our skin and tissues will become increasingly severe, making us unable to resist infections like cellulitis. Since any injury, even surgical, to the affected area can have this effect, amputation of a lymphedematous limb won’t improve our condition.
.
With help from the staff of Senator Arlen Specter, I was able to get my prescription garments covered until last December. Now, like many others, I’m up a creek–and scared. Without insurance coverage, we won’t be able to “live with” lymphedema. We’ll deteriorate with it. We’ll become unable to work, take care of ourselves and our families, or stay out of hospital beds and emergency rooms. We’ll have infection after infection, and we’ll need increasingly powerful antibiotics for them because we’ll become resistant to the bacteria that cause them.
.
And then, from a disease that’s treatable and controllable, we’ll die.
.
Barbara Pilvin